These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 10672857)
1. Intracoronary enalaprilat improves metabolic coronary vasodilation in patients with idiopathic dilated cardiomyopathy. Mohri M; Tagawa H; Egashira K; Takeshita A J Cardiovasc Pharmacol; 2000 Feb; 35(2):249-55. PubMed ID: 10672857 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Nikolaidis LA; Doverspike A; Huerbin R; Hentosz T; Shannon RP Circulation; 2002 Jun; 105(23):2785-90. PubMed ID: 12057995 [TBL] [Abstract][Full Text] [Related]
3. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. Wittstein IS; Kass DA; Pak PH; Maughan WL; Fetics B; Hare JM J Am Coll Cardiol; 2001 Aug; 38(2):429-35. PubMed ID: 11499734 [TBL] [Abstract][Full Text] [Related]
4. Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy. Foult JM; Tavolaro O; Antony I; Nitenberg A Eur Heart J; 1989 Nov; 10 Suppl F():97-100. PubMed ID: 2559850 [TBL] [Abstract][Full Text] [Related]
5. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. Kuga T; Mohri M; Egashira K; Hirakawa Y; Tagawa T; Shimokawa H; Takeshita A J Am Coll Cardiol; 1997 Jul; 30(1):108-12. PubMed ID: 9207629 [TBL] [Abstract][Full Text] [Related]
6. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. Prasad A; Husain S; Quyyumi AA J Am Coll Cardiol; 1999 Mar; 33(3):796-804. PubMed ID: 10080484 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Hornig B; Arakawa N; Haussmann D; Drexler H Circulation; 1998 Dec 22-29; 98(25):2842-8. PubMed ID: 9860785 [TBL] [Abstract][Full Text] [Related]
8. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. Shiode N; Morishima N; Nakayama K; Yamagata T; Matsuura H; Kajiyama G J Am Coll Cardiol; 1996 Feb; 27(2):304-10. PubMed ID: 8557898 [TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. Nakamura M; Funakoshi T; Arakawa N; Yoshida H; Makita S; Hiramori K J Am Coll Cardiol; 1994 Nov; 24(5):1321-7. PubMed ID: 7930256 [TBL] [Abstract][Full Text] [Related]
10. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Foult JM; Tavolaro O; Antony I; Nitenberg A Circulation; 1988 Feb; 77(2):337-44. PubMed ID: 2827913 [TBL] [Abstract][Full Text] [Related]
11. Adrenomedullin causes coronary vasodilation in humans: effects of inhibition of nitric oxide synthesis. Ueda K; Teragawa H; Kimura M; Matsuda K; Higashi Y; Yamagata T; Oshima T; Yoshizumi M; Chayama K J Cardiovasc Pharmacol; 2005 Oct; 46(4):534-9. PubMed ID: 16160609 [TBL] [Abstract][Full Text] [Related]
13. Important role of endogenous hydrogen peroxide in pacing-induced metabolic coronary vasodilation in dogs in vivo. Yada T; Shimokawa H; Hiramatsu O; Shinozaki Y; Mori H; Goto M; Ogasawara Y; Kajiya F J Am Coll Cardiol; 2007 Sep; 50(13):1272-8. PubMed ID: 17888845 [TBL] [Abstract][Full Text] [Related]
14. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers. Nakamura M; Funakoshi T; Yoshida H; Arakawa N; Suzuki T; Hiramori K J Cardiovasc Pharmacol; 1992 Dec; 20(6):949-54. PubMed ID: 1282598 [TBL] [Abstract][Full Text] [Related]
15. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies. Sudhir K; MacGregor JS; Gupta M; Barbant SD; Redberg R; Yock PG; Chatterjee K Circulation; 1993 Mar; 87(3):931-8. PubMed ID: 8383016 [TBL] [Abstract][Full Text] [Related]
16. Effect of enalaprilat on nitric oxide activity in coronary artery disease. Prasad A; Husain S; Quyyumi AA Am J Cardiol; 1999 Jul; 84(1):1-6. PubMed ID: 10404842 [TBL] [Abstract][Full Text] [Related]
17. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Quyyumi AA; Dakak N; Andrews NP; Gilligan DM; Panza JA; Cannon RO Circulation; 1995 Aug; 92(3):320-6. PubMed ID: 7634444 [TBL] [Abstract][Full Text] [Related]